

<b>General information about company</b>	
Scrip code*	519471
NSE Symbol*	NOTLISTED
MSEI Symbol*	NOTLISTED
ISIN*	INE072V01017
Name of company	AMBAR PROTEIN INDUSTRIES LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	30-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	20-05-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Edible Oils
Start date and time of board meeting	30-05-2026 15:30
End date and time of board meeting	30-05-2026 16:15
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	30-05-2025
Indicate Company website link for updated RPT policy of the Company	<a href="https://ambarprotein.com/investors/Policies">https://ambarprotein.com/investors/Policies</a>
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No The Company has neither obtained/taken loan from any party nor issued any debentures.

Financial Results – Ind-AS			
Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period	01-01-2026	01-04-2025	
Date of end of reporting period	31-03-2026	31-03-2026	
Whether results are audited or unaudited	Audited	Audited	
Nature of report standalone or consolidated	Standalone	Standalone	
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>1</b>	<b>Income</b>		
	Revenue from operations	14679.97	50065.59
	Other income	21.87	78.12
	<b>Total income</b>	<b>14701.84</b>	<b>50143.71</b>
<b>2</b>	<b>Expenses</b>		
(a)	Cost of materials consumed	15130.54	48776.77
(b)	Purchases of stock-in-trade	0	0.43
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-1168.4	-980.72
(d)	Employee benefit expense	62.78	236.04
(e)	Finance costs	54.75	202.96
(f)	Depreciation, depletion and amortisation expense	35.5	136.74
(g)	<b>Other Expenses</b>		
1	OTHER EXPENSES	243.64	832.9
	<b>Total other expenses</b>	<b>243.64</b>	<b>832.9</b>
	<b>Total expenses</b>	<b>14358.81</b>	<b>49205.12</b>
3	<b>Total profit before exceptional items and tax</b>	<b>343.03</b>	<b>938.59</b>
4	Exceptional items	0	0
5	<b>Total profit before tax</b>	<b>343.03</b>	<b>938.59</b>
6	<b>Tax expense</b>		
7	Current tax	80.41	238.34
8	Deferred tax	16.21	-2.41
9	<b>Total tax expenses</b>	<b>96.62</b>	<b>235.93</b>
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	<b>Net Profit Loss for the period from continuing operations</b>	<b>246.41</b>	<b>702.66</b>
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	<b>Net profit (loss) from discontinued operation after tax</b>	<b>0</b>	<b>0</b>
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	<b>Total profit (loss) for period</b>	<b>246.41</b>	<b>702.66</b>
17	Other comprehensive income net of taxes	1.23	1.71
18	<b>Total Comprehensive Income for the period</b>	<b>247.64</b>	<b>704.37</b>
19	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21	<b>Details of equity share capital</b>		
	Paid-up equity share capital	575	575
	Face value of equity share capital	10	10
22	Reserves excluding revaluation reserve	3601.88	
23	<b>Earnings per share</b>		
i	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	4.29	12.22
	Diluted earnings (loss) per share from continuing operations	4.29	12.22
ii	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
iii	<b>Earnings per equity share (for continuing and discontinued operations)</b>		
	Basic earnings (loss) per share from continuing and discontinued operations	4.29	12.22
	Diluted earnings (loss) per share from continuing and discontinued operations	4.29	12.22
24	Debt equity ratio		Textual Information( 1)
25	Debt service coverage ratio		Textual Information( 2)
26	Interest service coverage ratio		Textual Information( 3)
27	<b>Disclosure of notes on financial results</b>	<b>Textual Information(4)</b>	

<b>Text Block</b>	
Textual Information(4)	<p>NOTES:</p> <ol style="list-style-type: none"><li>1. These financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment thereafter and other accounting principles generally accepted in India.</li><li>2. The Audit Committee reviewed the above results. The Board of Directors in their meeting held on 30th May, 2026 approved the above results.</li><li>3. These result has been audited by the Statutory Auditor of the company who has issued an unmodified audit report on the standalone annual financial statement for the year ended 31st March, 2026.</li><li>4. The Company has only one business segment i.e. Manufacturing and selling of Edible Oil.</li><li>5. Figures for the previous year have been regrouped, recast and rearranged, wherever necessary.</li><li>6. The figures for the quarter ended 31st March, 2026 and 31st March, 2025 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the respective Financial year, also the result at the end of the third quarter were only reviewed and not subject to Audit.</li></ol>

Statement of Asset and Liabilities		
Particulars		Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	31-03-2026
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
<b>Assets</b>		
<b>1 Non-current assets</b>		
Property, plant and equipment		1832.54
Capital work-in-progress		103.35
Investment property		
Goodwill		0
Other intangible assets		0
Intangible assets under development		
Biological assets other than bearer plants		
Investments accounted for using equity method		
<b>Non-current financial assets</b>		
Non-current investments		2
Trade receivables, non-current		
Loans, non-current		15.12
<b>Other non-current financial assets</b>		
1 Other non-current financial assets		327.23
2		
3		
4		
5		
<b>Details of other non-current financial assets</b>		
	<b>Total of other non-current financial assets</b>	<b>327.23</b>
	<b>Total non-current financial assets</b>	<b>344.35</b>
	Deferred tax assets (net)	0
<b>Other non-current assets</b>		
1		
2		
3		
4		
5		
<b>Details of other non-current assets</b>		
	<b>Total of other non-current assets</b>	<b>2280.24</b>
	<b>Total non-current assets</b>	<b>2280.24</b>
<b>2 Current assets</b>		
Inventories		3867.11
<b>Current financial asset</b>		
Current investments		0
Trade receivables, current		1017.57
Cash and cash equivalents		122.94
Bank balance other than cash and cash equivalents		7.63
Loans, current		1.71
<b>Other current financial assets</b>		
1		
2		
3		
4		
5		
<b>Details of other current financial assets</b>		
	<b>Total of Other current financial assets</b>	<b>1149.85</b>
	<b>Total current financial assets</b>	<b>1149.85</b>
	Current tax assets (net)	
<b>Other current assets</b>		
1 Other current assets		905.46
2		
3		
4		
5		
<b>Details of other current assets</b>		
	<b>Total of other current assets</b>	<b>905.46</b>
	<b>Total current assets</b>	<b>5922.42</b>
3 Non-current assets classified as held for sale		
4 Regulatory deferral account debit balances and related deferred tax Assets		
	<b>Total assets</b>	<b>8202.66</b>
<b>Equity and liabilities</b>		
<b>1 Equity</b>		
<b>Equity attributable to owners of parent</b>		
Equity share capital		575
Other equity		3601.88
	<b>Total equity attributable to owners of parent</b>	<b>4176.88</b>
Non controlling interest		
	<b>Total equity</b>	<b>4176.88</b>
<b>2 Liabilities</b>		
<b>Non-current liabilities</b>		
<b>Non-current financial liabilities</b>		
Borrowings, non-current		12.96
<b>Trade Payables, non-current</b>		
(A) Total outstanding dues of micro enterprises and small enterprises		
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises		
	<b>Total Trade payable</b>	

	<b>Other non-current financial liabilities</b>	
1		
2		
3		
4		
5		
	<b>Details of other non-current financial liabilities</b>	
	<b>Total of other non-current financial liabilities</b>	
	<b>Total non-current financial liabilities</b>	<b>12.96</b>
	Provisions, non-current	28.83
	Deferred tax liabilities (net)	202.72
	Deferred government grants, Non-current	
	<b>Other non-current liabilities</b>	
1		
2		
3		
4		
5		
	<b>Details of other non-current liabilities</b>	
	<b>Total of other non-current liabilities</b>	
	<b>Total non-current liabilities</b>	<b>244.51</b>
	<b>Current liabilities</b>	
	<b>Current financial liabilities</b>	
	Borrowings, current	2579.29
	<b>Trade Payables, current</b>	
	(A) Total outstanding dues of micro enterprises and small enterprises	155.26
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	737.32
	<b>Total Trade payable</b>	<b>892.58</b>
	<b>Other current financial liabilities</b>	
1		
2		
3		
4		
5		
	<b>Details of other current financial liabilities</b>	
	<b>Total of other current financial liabilities</b>	
	<b>Total current financial liabilities</b>	<b>3471.87</b>
	<b>Other current liabilities</b>	
1	Other current liabilities	40.21
2		
3		
4		
5		
	<b>Details of other current liabilities</b>	
	<b>Total of other current liabilities</b>	<b>40.21</b>
	Provisions, current	35.02
	Current tax liabilities (Net)	234.17
	Deferred government grants, Current	
	<b>Total current liabilities</b>	<b>3781.27</b>
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	<b>Total liabilities</b>	<b>4025.78</b>
	<b>Total equity and liabilities</b>	<b>8202.66</b>
	<b>Disclosure of notes on assets and liabilities</b>	

<b>Other Comprehensive Income</b>			
	Date of start of reporting period	01-01-2026	01-04-2025
	Date of end of reporting period	31-03-2026	31-03-2026
	Whether results are audited or unaudited	Audited	Audited
	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss	-1.23	-1.71
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	1.23	1.71

Cash flow statement, indirect		
Particulars		Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	31-03-2026
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
Part I	Blue color marked fields are non-mandatory.	
<b>1</b>	<b>Statement of cash flows</b>	
	Cash flows from used in operating activities	
	Profit before tax	938.59
<b>2</b>	<b>Adjustments for reconcile profit (loss)</b>	
	Adjustments for finance costs	202.96
	Adjustments for decrease (increase) in inventories	-1824.34
	Adjustments for decrease (increase) in trade receivables, current	1010.19
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-262.89
	Adjustments for decrease (increase) in other non-current assets	-0.15
	Adjustments for other financial assets, non-current	0
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	528.32
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	11.4
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	136.74
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	13.16
	Adjustments for provisions, non-current	-2.68
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0.3
	Adjustments for interest income	1.46
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	<b>Total adjustments for reconcile profit (loss)</b>	<b>-189.05</b>
	<b>Net cash flows from (used in) operations</b>	<b>749.54</b>
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	379.34
	Other inflows (outflows) of cash	-74.06
	<b>Net cash flows from (used in) operating activities</b>	<b>296.14</b>
<b>3</b>	<b>Cash flows from used in investing activities</b>	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	0
	Purchase of property, plant and equipment	156.53
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	1.51
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0.3
	Interest received	1.46
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	76.28
	<b>Net cash flows from (used in) investing activities</b>	<b>-80</b>
<b>4</b>	<b>Cash flows from used in financing activities</b>	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0

	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	3.35
	Payments of lease liabilities	0
	Dividends paid	0
	Interest paid	202.95
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	<b>Net cash flows from (used in) financing activities</b>	<b>-206.3</b>
	<b>Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</b>	<b>9.84</b>
5	<b>Effect of exchange rate changes on cash and cash equivalents</b>	
	Effect of exchange rate changes on cash and cash equivalents	0
	<b>Net increase (decrease) in cash and cash equivalents</b>	<b>9.84</b>
	Cash and cash equivalents cash flow statement at beginning of period	113.1
	<b>Cash and cash equivalents cash flow statement at end of period</b>	<b>122.94</b>

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)																		
Sr. No.	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness incurred to make or give loans, int corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/any other etc.)	Details of other indebtedness	Cost	T
1	AMBAR PROTEIN INDUSTRIES LIMITED	AABCM0541N	ANKUR OIL INDUSTRIES	AABFA6682K	Entity in which one or more Key Managerial Personnel has significant influence / control	Sale of goods or services		40000	APPROVED			20345.51	0	0				
2	AMBAR PROTEIN INDUSTRIES LIMITED	AABCM0541N	ANKUR OIL INDUSTRIES	AABFA6682K	Entity in which one or more Key Managerial Personnel has significant influence / control	Any other transaction	RENT RECEIVED	100	APPROVED			36.88	0	0				
3	AMBAR PROTEIN INDUSTRIES LIMITED	AABCM0541N	Pradeep Chunilal Khetani	ACNPK4104A	Key management personnel	Remuneration			NA			10.5	0	0				
4	AMBAR PROTEIN INDUSTRIES LIMITED	AABCM0541N	Vachhani Jayprakash Jairambhai	AAJPV1140M	Key management personnel	Remuneration			NA			10.5	0	0				
5	AMBAR PROTEIN INDUSTRIES LIMITED	AABCM0541N	Bharat Dasrathbhai Patel	ACIPP6387P	Director	Any other transaction	Commission paid		NA			3.6	0	0				
6	AMBAR PROTEIN INDUSTRIES LIMITED	AABCM0541N	Mehul Ashokkumar Mehta	BDQPM3112D	Key management personnel	Remuneration			NA			2.97	0	0				
7	AMBAR PROTEIN INDUSTRIES LIMITED	AABCM0541N	Dhirajkumar Mohanbhai Panchal	AKHPP8642C	Key management personnel	Remuneration			NA			4.7	0	0				
8	AMBAR PROTEIN INDUSTRIES LIMITED	AABCM0541N	ANKUR OIL INDUSTRIES	AABFA6682K	Entity in which one or more Key Managerial Personnel has significant influence / control	Any other transaction	Freight Paid	50	APPROVED			0	0	0				
9	AMBAR PROTEIN INDUSTRIES LIMITED	AABCM0541N	Pradeep Chunilal Khetani	ACNPK4104A	Key management personnel	Interest paid			APPROVED			4.94	0	0				
10	AMBAR PROTEIN INDUSTRIES LIMITED	AABCM0541N	Vachhani Jayprakash Jairambhai	AAJPV1140M	Key management personnel	Interest paid			APPROVED			1.2	0	0				
11	AMBAR PROTEIN INDUSTRIES LIMITED	AABCM0541N	Bharat Dasrathbhai Patel	ACIPP6387P	Director	Interest paid			APPROVED			14.05	0	0				
12	AMBAR PROTEIN INDUSTRIES LIMITED	AABCM0541N	Shirish Dasrathbhai Patel	AKRPP1251B	Director	Interest paid			APPROVED			16.88	0	0				
13	AMBAR PROTEIN INDUSTRIES LIMITED	AABCM0541N	Shobhanaben Jayprakash Vachhani	AATPV1697B	Director	Interest paid			APPROVED			14.56	0	0				
14	AMBAR PROTEIN INDUSTRIES LIMITED	AABCM0541N	Dashrathbhai Ashabhai Patel	ACIPP6386N	Director	Interest paid			APPROVED			2.84	0	0				
Total value of transaction during the reporting period											20469.13							

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	FENIL P SHAH & ASSOCIATES	Yes	30-11-2028

